Close Menu
Business Voice NowBusiness Voice Now
    Facebook X (Twitter) Instagram
    Business Voice NowBusiness Voice Now
    Subscribe
    • Markets
      • IPO
      • Market News
    • Business
      • FMCG
      • Retail
      • Quick Commerce
      • Startups
    • Healthcare
    • Technology
    • Energy
    • Voices
      • Entrepreneur – CXO Stories
      • Corporate Office story
    • E Magazine
      • Year 2026
        • November 2026
        • October 2026
        • September 2026
        • August 2026
        • July 2026
    Business Voice NowBusiness Voice Now
    Home»Press Release»IPCA Laboratories Ltd launches Diulcus® to address Diabetic Foot Ulcer in India
    Press Release

    IPCA Laboratories Ltd launches Diulcus® to address Diabetic Foot Ulcer in India

    WebDeskBy WebDeskAugust 28, 2024No Comments4 Mins Read
    Share Facebook Twitter Pinterest LinkedIn Tumblr Email
    Follow Us
    Google News Flipboard Threads
    Share
    Facebook Twitter LinkedIn Pinterest Email

    New Delhi [India], August 27: As per the ICMR-INDIAB (2023) study, 10 crore people in India suffer from diabetes, with an additional 13.6 crore people affected by pre-diabetes. This significant health concern positions India to become the diabetes capital of the world by 2030.

    In response to this serious healthcare challenge, IPCA Laboratories Ltd proudly announces the launch of Diulcus®, a novel product aimed at addressing the challenges of Diabetic Foot Ulcer (DFU) in the Indian market. Diulcus®, developed by NovaLead Pharma Pvt Ltd, a pioneer in drug repurposing, represents a significant advancement in the management of DFU. The product has received approval from the Central Drugs Standard Control Organization (CDSCO) and was partially funded by the Biotechnology Industry Research Assistance Council (BIRAC), a Government of India enterprise.

    The launch event was graced by esteemed personalities, including Sri. Ajit Jain, Dr A.P.S. Suri, Dr Achintya Sharma, Dr Anil Pareek, Sri Sunil Ghai, Sri. Supreet Deshpande.

    During phase 3 trials in India, Diulcus® demonstrated remarkable efficacy, with a 60.3% ulcer closure rate within three months of treatment. Remarkably, patients continued to show an ulcer closure rate of 77.20% over six months, even after stopping treatment at three months. These results are among the best observed for any pharmaceutical preparation used in DFU treatment.

    Sri. Ajit Jain, Managing Director of IPCA Laboratories Ltd, expressed his enthusiasm about the launch, stating, “With over 15% of diabetic patients suffering from DFU at least once in their lifetime, DFU is the most prevalent complication caused by chronic diabetes. The approval of this patented repurposed drug is significant because DFU is the leading cause of lower limb amputations globally. We are delighted to partner with NovaLead Pharma Pvt Ltd through an IP licensing arrangement to bring Diulcus® to DFU patients in India. It demonstrates IPCA’s commitment towards the patients suffering from unmet medical needs and its focus on diabetes therapy.”

    Dr. A.P.S. Suri, Foot Care Specialist (Podiatrist), said, “With the launch of Diulcus®, we are writing a new chapter in the treatment of diabetic foot ulcers. This product can not only revolutionize the treatment of DFU but also help reduce the complications associated with it, such as amputation, infection, and long-term pain. Given the rising incidence of diabetic foot ulcers in India, this product will not only be an important tool for physicians but can also significantly improve the quality of life of patients. This product is effective in helping in healing diabetic ulcers, helping them heal faster and preventing amputation of the feet. I congratulate IPCA Laboratories Limited and NovaLead Pharma Private Limited for bringing this important innovation to the Indian market and hope that this product will become a ray of hope for millions of patients in our country.”

    Diulcus® will be made available to DFU patients by IPCA Laboratories Ltd. (IPCA) through an exclusive IP licensing arrangement with NovaLead Pharma PVT LTD for the Indian Market beginning in August 2024.

    For further details on the product, please consult your physician or write to savethefoot@ipca.com.

    About Diabetic Foot Ulcer (DFU)

    Over 537 million adults are living with diabetes globally, and the number is predicted to rise to 643 million by 2030. About 15% of diabetics suffer from DFU at least once in their lifetime, with 25% of DFUs eventually requiring amputation. DFU is a leading cause of lower extremity amputation. The five-year mortality post-amputation is 46%. DFU is a serious disease with very limited drug options and a very high cost of treatment.

    About Diulcus® (Esmolol Ilydrochloride)

    Diulcus® is a prescription medicine used to treat people with diabetic foot ulcer with no clinical infection. Infected DFUs need to be first treated for infection if existing and then put on Diulcus® treatment for wound closure. A doctor will perform independent assessment of DFU extent to determine the dose to be applied topically on the patient’s DFU. Treating clinicians are advised to refer to the full prescribing information of Diulcus®.

    About IPCA Laboratories Ltd (IPCA)

    IPCA is a fully integrated pharmaceutical company with a strong thrust on exports. IPCA is vertically integrated and produces Finished Dosage Forms (FDFs) and Active Pharmaceutical Ingredients (APIs).

    If you have any objection to this press release content, kindly contact pr.error.rectification@gmail.com to notify us. We will respond and rectify the situation in the next 24 hours.

    PR press-release
    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
    WebDesk
    • Website

    Related Posts

    Blue Cloud Softech Solutions Q2 FY27 Revenue Rises 19% to Rs 300.79 Crore; Net Profit Stands at Rs 9.93 Crore

    November 16, 2026

    Maiden Forgings H1 FY27 Total Income Soars 24.86% to Rs 139.04 Cr; EBITDA Surges 110.81%, Net Profit Jumps 233.12%

    November 16, 2026

    DEV Information Technology Secures Two Government Orders from Vadodara Municipal Corporation & Gujarat Metro Rail Corporation Worth Rs 17.08 Cr

    November 16, 2026

    Comments are closed.

    Recent Post
    • Blue Cloud Softech Solutions Q2 FY27 Revenue Rises 19% to Rs 300.79 Crore; Net Profit Stands at Rs 9.93 Crore
    • Srinibas Pradhan Constructions Reports 17.18% Growth in EBITDA and 33.87% Growth in PAT
    • Maiden Forgings H1 FY27 Total Income Soars 24.86% to Rs 139.04 Cr; EBITDA Surges 110.81%, Net Profit Jumps 233.12%
    • DEV Information Technology Secures Two Government Orders from Vadodara Municipal Corporation & Gujarat Metro Rail Corporation Worth Rs 17.08 Cr
    • Hirect to supply Made In India IGBT-based Propulsion Equipment to Railways in an order worth ₹133.38 crore
    • Chaaya Furnitures Launches Personalised, Made-to-Order Masterpieces to Redefine Indian Homes
    • Duroply Showcases its Built-to-Last Legacy
    • Austere Systems Announces H1 FY27 Results

    Type above and press Enter to search. Press Esc to cancel.